FY2027 EPS Forecast for Spectral AI Reduced by Analyst

Spectral AI, Inc. (NASDAQ:MDAI) – Research analysts at Northland Securities decreased their FY2027 earnings estimates for shares of Spectral AI in a research report issued on Wednesday, November 11th. Northland Securities analyst L. Horton now anticipates that the company will earn ($0.35) per share for the year, down from their previous forecast of ($0.34). Northland Securities has a “Strong-Buy” rating on the stock. The consensus estimate for Spectral AI’s current full-year earnings is ($0.50) per share.

Spectral AI (NASDAQ:MDAI) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14). The company had revenue of $2.86 million for the quarter, compared to analyst estimates of $5.33 million.

MDAI has been the topic of a number of other research reports. Wall Street Zen upgraded Spectral AI from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Weiss Ratings raised Spectral AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, October 28th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $4.00.

Spectral AI Stock Down 4.3%

Shares of NASDAQ:MDAI opened at $1.35 on Friday. Spectral AI has a 12-month low of $1.18 and a 12-month high of $2.97. The business has a 50 day moving average of $1.57 and a 200-day moving average of $1.69. The stock has a market cap of $43.46 million, a PE ratio of -4.09 and a beta of 1.25.

Institutional Trading of Spectral AI

An institutional investor recently bought a new position in Spectral AI stock. Rathbones Group PLC acquired a new stake in Spectral AI, Inc. (NASDAQ:MDAI) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 87,045 shares of the company’s stock, valued at approximately $144,000. Rathbones Group PLC owned 0.27% of Spectral AI as of its most recent SEC filing. Institutional investors own 67.08% of the company’s stock.

About Spectral AI

Spectral AI, Inc. is a medical diagnostic technology company focused on using artificial intelligence and advanced imaging to support earlier, more objective assessment of wound healing. The company develops predictive diagnostic systems intended to help clinicians evaluate wounds and make treatment decisions. Its principal product is the DeepView System, a noninvasive imaging and artificial intelligence platform designed to assess burn wounds and predict the likelihood that injured tissue will heal without surgical intervention.